{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T14:31:07Z","timestamp":1763389867431},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T00:00:00Z","timestamp":1724889600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>To explore the potential of testosterone therapy in managing cytopenias in myelodysplastic neoplasm and investigate the link between hypogonadism and hematologic malignancies. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A case of a patient with intermediate-risk myelodysplastic neoplasm and hypogonadism treated with testosterone replacement therapy is presented. Testosterone, prostate specific antigen, and erythropoietin levels were checked prior to therapy initiation and 3 months after. Blood counts were monitored over time. This is followed by a literature review of testosterone use in myelodysplastic neoplasm and the prevalence of hypogonadism in hematologic malignancies. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The patient showed sustained improvement in anemia with testosterone therapy and reported subjective improvement in his weakness and fatigue. This improvement occurred even in the setting of an undetectable follow up erythropoietin level. His repeat prostate specific antigen levels remained low, while testosterone levels showed marked improvement. The literature review demonstrated positive response rates for testosterone in treating myelodysplastic neoplasm-related cytopenias, and showed a higher incidence of hypogonadism in hematologic malignancies. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Our review suggests that the use of testosterone in low and intermediate-risk myelodysplastic neoplasm is underexplored and poses to have significant potential as a future therapeutic agent, after careful consideration of risks and benefits. In addition, the incidence of hypogonadism in myelodysplastic neoplasm and its potential impact on exacerbating cytopenias in myelodysplastic neoplasm warrants further investigation.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00432-024-05844-w","type":"journal-article","created":{"date-parts":[[2024,8,29]],"date-time":"2024-08-29T06:02:37Z","timestamp":1724911357000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Testosterone therapy as a novel approach to the management of cytopenias in myelodysplastic neoplasms: a review of literature and case report"],"prefix":"10.1007","volume":"150","author":[{"given":"John","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley","family":"Rockwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Divij","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Srabani","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,29]]},"reference":[{"issue":"1","key":"5844_CR1","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/s0272-6386(12)80246-0","volume":"17","author":"SH Ballal","year":"1991","unstructured":"Ballal SH, Domoto DT, Polack DC, Marciulonis P, Martin KJ (1991) Androgens potentiate the effects of erythropoietin in the treatment of anemia of end-stage renal disease. Am J Kidney Dis off J Natl Kidney Found 17(1):29\u201333. https:\/\/doi.org\/10.1016\/s0272-6386(12)80246-0","journal-title":"Am J Kidney Dis off J Natl Kidney Found"},{"issue":"2","key":"5844_CR2","first-page":"247","volume":"99","author":"M Beran","year":"1982","unstructured":"Beran M, Spitzer G, Verma DS (1982) Testosterone and synthetic and androgens improve the in vitro survival of human marrow progenitor cells in serum-free suspension cultures. J Lab Clin Med 99(2):247\u2013253","journal-title":"J Lab Clin Med"},{"issue":"6","key":"5844_CR3","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1210\/jc.2009-2575","volume":"95","author":"MM Fern\u00e1ndez-Balsells","year":"2010","unstructured":"Fern\u00e1ndez-Balsells MM, Murad MH, Lane M et al (2010) Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 95(6):2560\u20132575. https:\/\/doi.org\/10.1210\/jc.2009-2575","journal-title":"J Clin Endocrinol Metab"},{"issue":"13","key":"5844_CR4","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1001\/archinte.166.13.1380","volume":"166","author":"L Ferrucci","year":"2006","unstructured":"Ferrucci L, Maggio M, Bandinelli S (2006) Low testosterone levels and the risk of anemia in older men and women. JAMA 166(13):1380\u20131388. https:\/\/doi.org\/10.1001\/archinte.166.13.1380","journal-title":"JAMA"},{"issue":"34","key":"5844_CR5","doi-asserted-by":"publisher","first-page":"5054","DOI":"10.1200\/JCO.2010.30.3818","volume":"28","author":"SB Fleishman","year":"2010","unstructured":"Fleishman SB, Khan H, Homel P et al (2010) Testosterone levels and quality of life in diverse male patients with cancers unrelated to androgens. J Clin Oncol 28(34):5054\u20135060. https:\/\/doi.org\/10.1200\/JCO.2010.30.3818","journal-title":"J Clin Oncol"},{"issue":"5","key":"5844_CR6","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1177\/2042098614548680","volume":"5","author":"A Grech","year":"2014","unstructured":"Grech A, Breck J, Heidelbaugh J (2014) Adverse effects of testosterone replacement therapy: an update on the evidence and controversy. Ther Adv Drug Saf 5(5):190\u2013200. https:\/\/doi.org\/10.1177\/2042098614548680","journal-title":"Ther Adv Drug Saf"},{"issue":"2","key":"5844_CR7","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/acel.12052","volume":"12","author":"W Guo","year":"2013","unstructured":"Guo W, Bachman E, Li M et al (2013) Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 12(2):280\u2013291. https:\/\/doi.org\/10.1111\/acel.12052","journal-title":"Aging Cell"},{"issue":"6","key":"5844_CR8","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1111\/j.1442-2042.2011.02757.x","volume":"18","author":"M Iijima","year":"2011","unstructured":"Iijima M, Shigehara K, Sugimoto K et al (2011) Myelodysplastic syndrome treated effectively with testosterone enanthate. Int J Urol 18(6):469\u2013471. https:\/\/doi.org\/10.1111\/j.1442-2042.2011.02757.x","journal-title":"Int J Urol"},{"issue":"3","key":"5844_CR9","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1080\/10428194.2018.1508664","volume":"60","author":"S John","year":"2019","unstructured":"John S, Sharma N, Sborov DW et al (2019) Most multiple myeloma patients have low testosterone. Leuk Lymphoma 60(3):836\u2013838. https:\/\/doi.org\/10.1080\/10428194.2018.1508664","journal-title":"Leuk Lymphoma"},{"key":"5844_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.2147\/CMAR.S240600","volume":"13","author":"R Lewis","year":"2021","unstructured":"Lewis R, Bewersdorf JP, Zeidan AM (2021) Clinical management of anemia in patients with myelodysplastic syndromes: an update on emerging therapeutic options. Cancer Manag Res 13:645\u2013657. https:\/\/doi.org\/10.2147\/CMAR.S240600","journal-title":"Cancer Manag Res"},{"issue":"12","key":"5844_CR11","first-page":"1588","volume":"91","author":"L Malcovati","year":"2006","unstructured":"Malcovati L, Della Porta MG, Cazzola M (2006) Predicting survival and leukemic evolution in patients with myelodysplastic syndrome. Haematologica 91(12):1588\u20131590","journal-title":"Haematologica"},{"issue":"Supplement 1","key":"5844_CR12","doi-asserted-by":"publisher","first-page":"6484","DOI":"10.1182\/blood-2023-186427","volume":"142","author":"C Mei","year":"2023","unstructured":"Mei C, Xie Y, Shao Y, Ge Z, Tong H (2023) Recombinant human erythropoietin combined with all-trans retinoic acid and testosterone undecanoate in the treatment of anemia in patients with lower-risk myelodysplastic syndromes: updated results of a multicenter, single-arm, prospective trial. Blood 142(Supplement 1):6484\u20136484. https:\/\/doi.org\/10.1182\/blood-2023-186427","journal-title":"Blood"},{"issue":"5","key":"5844_CR13","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1182\/blood.V45.5.665.665","volume":"45","author":"Y Moriyama","year":"1975","unstructured":"Moriyama Y, Fisher J (1975) Effects of testosterone and erythropoietin on erythroid colony formation in human bone marrow cultures. Blood 45(5):665\u2013670. https:\/\/doi.org\/10.1182\/blood.V45.5.665.665","journal-title":"Blood"},{"issue":"7","key":"5844_CR14","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/j.1742-1241.2006.00992.x","volume":"60","author":"T Mulligan","year":"2006","unstructured":"Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C (2006) Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 60(7):762\u2013769. https:\/\/doi.org\/10.1111\/j.1742-1241.2006.00992.x","journal-title":"Int J Clin Pract"},{"key":"5844_CR15","doi-asserted-by":"publisher","first-page":"1135160","DOI":"10.3389\/fonc.2023.1135160","volume":"13","author":"M Nassani","year":"2023","unstructured":"Nassani M, Fakih RE, Passweg J et al (2023) The role of androgen therapy in acquired aplastic anemia and other bone marrow failure syndromes. Front Oncol 13:1135160. https:\/\/doi.org\/10.3389\/fonc.2023.1135160","journal-title":"Front Oncol"},{"issue":"2","key":"5844_CR16","first-page":"136","volume":"2","author":"EN Oliva","year":"2012","unstructured":"Oliva EN, Finelli C, Santini V et al (2012) Quality of life and physicians\u2019 perception in myelodysplastic syndromes. Am J Blood Res 2(2):136\u2013147","journal-title":"Am J Blood Res"},{"issue":"10","key":"5844_CR17","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.40030","volume":"6","author":"KM Pencina","year":"2023","unstructured":"Pencina KM, Travison TG, Artz AS et al (2023) Efficacy of testosterone replacement therapy in correcting anemia in men with hypogonadism: a randomized clinical trial. JAMA Netw Open 6(10):e2340030. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.40030","journal-title":"JAMA Netw Open"},{"issue":"3","key":"5844_CR18","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/BF00320369","volume":"54","author":"A Riccardi","year":"1987","unstructured":"Riccardi A, Giordano M, Girino M et al (1987) Refractory cytopenias: clinical course according to bone marrow cytology and cellularity. Blut 54(3):153\u2013163. https:\/\/doi.org\/10.1007\/BF00320369","journal-title":"Blut"},{"issue":"17","key":"5844_CR19","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.020562","volume":"10","author":"MM Shores","year":"2021","unstructured":"Shores MM, Walsh TJ, Korpak A et al (2021) Association between testosterone treatment and risk of incident cardiovascular events among US male veterans with low testosterone levels and multiple medical comorbidities. J Am Heart Assoc 10(17):e020562. https:\/\/doi.org\/10.1161\/JAHA.120.020562","journal-title":"J Am Heart Assoc"},{"key":"5844_CR20","first-page":"1872","volume":"361","author":"A Tefferi","year":"2009","unstructured":"Tefferi A, Vardiman J (2009) Myelodysplast Syndr 361:1872\u20131885","journal-title":"Myelodysplast Syndr"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-024-05844-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-024-05844-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T19:05:21Z","timestamp":1727377521000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-024-05844-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,29]]},"references-count":20,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["5844"],"URL":"https:\/\/doi.org\/10.1007\/s00432-024-05844-w","relation":{},"ISSN":["1432-1335"],"issn-type":[{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2024,8,29]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The participant has consented to the publication of the report to the journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"404"}}